Viking Therapeutics shares slip after a wider Q3 loss of $1.55 per share
Net loss doubled to $183.2 million, and retail investors balked at CEO Brian Lian's estimate that VK2735 is about two and a half years from launch.
Recap by typeshit. Full story at Yahoo Finance.